[HTML][HTML] Recommendations from the AML molecular MRD expert advisory board
The standard-of-care treatment for patients with acute myeloid leukemia (AML) is being
challenged by new classes of targeted therapies, including FLT3, IDH and BCL2 inhibitors …
challenged by new classes of targeted therapies, including FLT3, IDH and BCL2 inhibitors …
Recommendations from the AML molecular MRD expert advisory board
S Scott, A Devonshire, R Dillon, C Thiede… - Leukemia - pubmed.ncbi.nlm.nih.gov
Recommendations from the AML molecular MRD expert advisory board Recommendations
from the AML molecular MRD expert advisory board Leukemia. 2024 May 23. doi: 10.1038/s41375-024-02275-x …
from the AML molecular MRD expert advisory board Leukemia. 2024 May 23. doi: 10.1038/s41375-024-02275-x …
[引用][C] Recommendations from the AML molecular MRD expert advisory board.
S Scott, A Devonshire, R Dillon, C Thiede, NCP Cross… - Leukemia, 2024 - europepmc.org
Recommendations from the AML molecular MRD expert advisory board. - Abstract - Europe
PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers …
PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers …
[PDF][PDF] Recommendations from the AML molecular MRD expert advisory board
2024 - researchgate.net
The standard-of-care treatment for patients with acute myeloid leukemia (AML) is being
challenged by new classes of targeted therapies, including FLT3, IDH and BCL2 inhibitors …
challenged by new classes of targeted therapies, including FLT3, IDH and BCL2 inhibitors …